A Phase I trial of neuroprotective therapies for the treatment of neurological conditions caused by chemotherapy
Phase of Trial: Phase I
Latest Information Update: 12 Sep 2018
Price : $35 *
At a glance
- Drugs Neuroprotectants (Primary)
- Indications Neurodegenerative disorders
- Focus Adverse reactions
- 12 Sep 2018 I have assumed subjects to be healthy volunteers since this is a phase I trial. The trial may be carried out in patients. Please update the information when more details become available.Indications are taken from RDI profile.
- 12 Sep 2018 New trial record
- 27 Aug 2018 According to a Magnolia Neurosciences Corporation media release, the company expects to initiate this trial in the second half of 2019.